"Detection before disease"

header photo

Platform Technology for Determining Protein Conformation

A Novel Blood Test for Presymptomatic Detection of Alzheimer’s Disease

Alzheimer’s disease (AD) cases continue to increase without effective diagnosis and treatment solutions. Today, there is no successful test to diagnose AD at its earliest stages in healthy asymptomatic individuals to determine disease status. One reason may be the lack of validated biomarkers which prevents a preclinical AD diagnosis.   Presympto is developing a novel early detection blood test based on peptide ligands to be used before any signs of AD in healthy asymptomatic individuals to determine their status and risk for AD.

Our technology, Pronucleon™ peptides, involves custom-synthesized peptides that mimic the misfolding region of proteins such as Aβ.  Pronucleon™ peptides displayed specificity and sensitivity for Aβ oligomers; peptides showed preferential binding to AD RBC as compared to normal; our RBC flow cytometry assay exhibited differentiation between healthy and AD samples.

Our preliminary data sets the stage for an exciting new approach to diagnosing Alzheimer’s disease, allowing the medical community, the AD therapeutic community, and the public an opportunity to address this disease before its symptoms appear.

Our Vision

  • A simple detection using sequence-specific peptide synthesis
  • Ability to detect and screen for the early oligomer/aggregate form of amyloid
  • Deployable at a population screening level
  • Capable of detecting pathology in early staged disease (pre-cognitive)
  • Quantitative technology for following progression, or response to therapy
  • Brain imaging, ophthalmic testing, blood/CFS testing